Serum IGFBP-2 in systemic sclerosis as a prognostic factor of lung dysfunction

Area of Science:

• Rheumatology
• Pulmonology
• Biomarker Discovery

Background:

• Systemic sclerosis (SSc) is a rare autoimmune disease characterized by fibrosis.
• Interstitial lung disease (ILD) is a major cause of mortality in SSc patients.
• Novel biomarkers are needed to predict SSc-ILD progression.

Purpose of the Study:

• To identify specific biomarkers for predicting the evolution of SSc-ILD.
• To evaluate serum levels of IGFBP-2 as a potential prognostic factor.

Main Methods:

• Prospective study comparing serum biomarker levels in SSc patients with and without ILD, and healthy subjects.
• Longitudinal analysis of biomarker variations and pulmonary function tests over 2 years in a subgroup of SSc patients.
• Receiver Operating Characteristic (ROC) curve analysis to determine predictive value.

Main Results:

• Serum IGFBP-2 levels were significantly increased in SSc patients compared to healthy subjects.
• IGFBP-2 levels negatively correlated with pulmonary function (KCO) in SSc patients.
• IGFBP-2 variation positively correlated with KCO over 2 years; lower IGFBP-2 variation indicated pulmonary function deterioration.
• Baseline IGFBP-2 > 105 ng/ml predicted poor outcome (KCO < 70% predicted) at 2-year follow-up.

Conclusions:

• Serum IGFBP-2 may serve as a prognostic biomarker for SSc-ILD development and progression.
• IGFBP-2 levels and their variation can help predict pulmonary function decline in SSc patients.
• This finding offers potential for early intervention and improved patient management in SSc-ILD.